Drug Profile
Tidutamab - Xencor
Alternative Names: Anti-SSTR2 x anti-CD3 monoclonal antibody; SSTR2 x CD3; XmAb-18087Latest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal stromal tumours; Merkel cell carcinoma; Neuroendocrine tumours; Small cell lung cancer
Most Recent Events
- 31 Dec 2022 Discontinued - Phase-I for Gastrointestinal stromal tumours (In adolescents, In children, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (IV)
- 31 Dec 2022 Discontinued - Phase-I for Neuroendocrine tumours (In adolescents, In children, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (IV)
- 31 Dec 2022 Discontinued - Phase-I/II for Merkel cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)